Matches in SemOpenAlex for { <https://semopenalex.org/work/W2988750812> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2988750812 abstract "Abstract BACKGROUND Procaspase activating compound -1 (PAC-1) is a small molecule that catalyzes conversion of procaspase-3 to caspase-3 which induces apoptosis in cancer cells. Glioblastoma (GBM) is among the tumors with high concentrations of procaspase-3 and low levels of caspase-3. PAC-1 crosses the blood brain barrier and has been shown to synergize with temozolomide (TMZ) in canine malignant glioma and meningioma that arise spontaneously. METHODS This is a multicenter phase 1 dose-escalation study to assess the maximum tolerated dose (MTD) of PAC-1 administered days 1–21 in combination with TMZ days 8–12 at a dose of 150 mg/m2 of each 28 day cycle in subjects with recurrent anaplastic astrocytoma (AA) or GBM. A modified Fibonacci 3 + 3 design is used with up to 4 dose levels of PAC-1 (375, 500, 625 and 750 mg/day). Neurologic toxicity, including cognitive function, is closely monitored throughout the trial. INTERIM DATA: A total of 14 subjects have been enrolled to-date. Of these, 7 at dose level 1, PAC-1 375 mg/day (6 GBM, 1 AA; median age 58y, range 25–75) and 7 at dose level 2, PAC-1 500 mg/day (5 GBM, 2 AA; median age 51y, range 35–60). Best responses to-date were 2 subjects with a partial response and 2 with stable disease. Grade 3 (hepatotoxicity) and 4 (cerebral edema) was reported as possibly related to PAC-1 in 1 patient at dose level 1. The median number of cycles received was 4 (range, 1–12+) at dose level 1 and 2 (range, 1–3) at dose level 2. Enrollment to dose level 2 has been completed and data analysis is ongoing. Updated response and toxicity as well as pharmacokinetic data will be presented." @default.
- W2988750812 created "2019-11-22" @default.
- W2988750812 creator A5009427059 @default.
- W2988750812 creator A5010735832 @default.
- W2988750812 creator A5021641134 @default.
- W2988750812 creator A5027996458 @default.
- W2988750812 creator A5035708719 @default.
- W2988750812 creator A5076656358 @default.
- W2988750812 creator A5086594299 @default.
- W2988750812 creator A5090069473 @default.
- W2988750812 date "2019-11-01" @default.
- W2988750812 modified "2023-10-14" @default.
- W2988750812 title "ACTR-63. PHASE I DOSE ESCALATION STUDY OF PROCASPASE ACTIVATING COMPOUND-1 (PAC-1) IN COMBINATION WITH TEMOZOLOMIDE IN PATIENTS WITH RECURRENT ANAPLASTIC ASTROCYTOMA OR GLIOBLASTOMA" @default.
- W2988750812 doi "https://doi.org/10.1093/neuonc/noz175.105" @default.
- W2988750812 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6847026" @default.
- W2988750812 hasPublicationYear "2019" @default.
- W2988750812 type Work @default.
- W2988750812 sameAs 2988750812 @default.
- W2988750812 citedByCount "0" @default.
- W2988750812 crossrefType "journal-article" @default.
- W2988750812 hasAuthorship W2988750812A5009427059 @default.
- W2988750812 hasAuthorship W2988750812A5010735832 @default.
- W2988750812 hasAuthorship W2988750812A5021641134 @default.
- W2988750812 hasAuthorship W2988750812A5027996458 @default.
- W2988750812 hasAuthorship W2988750812A5035708719 @default.
- W2988750812 hasAuthorship W2988750812A5076656358 @default.
- W2988750812 hasAuthorship W2988750812A5086594299 @default.
- W2988750812 hasAuthorship W2988750812A5090069473 @default.
- W2988750812 hasBestOaLocation W29887508121 @default.
- W2988750812 hasConcept C126322002 @default.
- W2988750812 hasConcept C143998085 @default.
- W2988750812 hasConcept C2777389519 @default.
- W2988750812 hasConcept C2778227246 @default.
- W2988750812 hasConcept C2778880634 @default.
- W2988750812 hasConcept C2779083369 @default.
- W2988750812 hasConcept C29730261 @default.
- W2988750812 hasConcept C31760486 @default.
- W2988750812 hasConcept C502942594 @default.
- W2988750812 hasConcept C535046627 @default.
- W2988750812 hasConcept C61943457 @default.
- W2988750812 hasConcept C71924100 @default.
- W2988750812 hasConcept C90924648 @default.
- W2988750812 hasConcept C98274493 @default.
- W2988750812 hasConceptScore W2988750812C126322002 @default.
- W2988750812 hasConceptScore W2988750812C143998085 @default.
- W2988750812 hasConceptScore W2988750812C2777389519 @default.
- W2988750812 hasConceptScore W2988750812C2778227246 @default.
- W2988750812 hasConceptScore W2988750812C2778880634 @default.
- W2988750812 hasConceptScore W2988750812C2779083369 @default.
- W2988750812 hasConceptScore W2988750812C29730261 @default.
- W2988750812 hasConceptScore W2988750812C31760486 @default.
- W2988750812 hasConceptScore W2988750812C502942594 @default.
- W2988750812 hasConceptScore W2988750812C535046627 @default.
- W2988750812 hasConceptScore W2988750812C61943457 @default.
- W2988750812 hasConceptScore W2988750812C71924100 @default.
- W2988750812 hasConceptScore W2988750812C90924648 @default.
- W2988750812 hasConceptScore W2988750812C98274493 @default.
- W2988750812 hasLocation W29887508121 @default.
- W2988750812 hasLocation W29887508122 @default.
- W2988750812 hasOpenAccess W2988750812 @default.
- W2988750812 hasPrimaryLocation W29887508121 @default.
- W2988750812 hasRelatedWork W11687661 @default.
- W2988750812 hasRelatedWork W13487282 @default.
- W2988750812 hasRelatedWork W1366240 @default.
- W2988750812 hasRelatedWork W3582852 @default.
- W2988750812 hasRelatedWork W3625525 @default.
- W2988750812 hasRelatedWork W3706229 @default.
- W2988750812 hasRelatedWork W5363639 @default.
- W2988750812 hasRelatedWork W5705025 @default.
- W2988750812 hasRelatedWork W6961521 @default.
- W2988750812 hasRelatedWork W8061009 @default.
- W2988750812 isParatext "false" @default.
- W2988750812 isRetracted "false" @default.
- W2988750812 magId "2988750812" @default.
- W2988750812 workType "article" @default.